-
Je něco špatně v tomto záznamu ?
AminoBODIPY Conjugates for Targeted Drug Delivery Systems and Real-Time Monitoring of Drug Release
M. Porubský, S. Gurská, J. Stanková, M. Hajdúch, P. Džubák, J. Hlaváč
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- fluorescence MeSH
- fluorescenční barviva chemie MeSH
- glutathion metabolismus MeSH
- HeLa buňky MeSH
- hydroxychinoliny aplikace a dávkování farmakokinetika MeSH
- integrin alfaVbeta3 metabolismus MeSH
- lidé MeSH
- nosiče léků chemie farmakologie MeSH
- oligopeptidy chemie farmakologie MeSH
- sloučeniny boru chemie MeSH
- uvolňování léčiv MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
In this work, we report two concepts of drug delivery based on small-molecule drug conjugates with the ability of specific targeting and drug release monitoring via ratiometric fluorescence. The functionality of these concepts has been verified by two model systems consisting of three parts: (i) fluorescent aminoBODIPY for real-time detection of conjugate cleavage, (ii) a c(RGDfK) peptide specific for αvβ3 integrin receptors targeting angiogenesis in most solid tumors or redBODIPY for conjugate cleavage monitoring via FRET, and (iii) pegylated-2-phenyl-3-hydroxy-4(1H)-quinolinone (3HQ) as a model drug. The model drug release is based on a self-immolative disulfide linker sensitive to environments containing thiols, especially glutathione, which is overexpressed in cancer cells. The results show effective thiol-mediated cleavage of the fluorescent reporter and the subsequent liberation of the drug in a tube. The conjugate with c(RGDfK) was confirmed to penetrate the cells via interaction with integrin receptors. Drug release from this conjugate is possible to monitor inside the cells. Further, the synthetic approach to the conjugates and the method of fluorescence monitoring of the drug release have also been described.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22004227
- 003
- CZ-PrNML
- 005
- 20220127145425.0
- 007
- ta
- 008
- 220113s2021 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1021/acs.molpharmaceut.1c00219 $2 doi
- 035 __
- $a (PubMed)33961440
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Porubský, Martin $u Department of Organic Chemistry, Faculty of Science, Palacký University, Tr. 17. Listopadu 12, 771 46 Olomouc, Czech Republic
- 245 10
- $a AminoBODIPY Conjugates for Targeted Drug Delivery Systems and Real-Time Monitoring of Drug Release / $c M. Porubský, S. Gurská, J. Stanková, M. Hajdúch, P. Džubák, J. Hlaváč
- 520 9_
- $a In this work, we report two concepts of drug delivery based on small-molecule drug conjugates with the ability of specific targeting and drug release monitoring via ratiometric fluorescence. The functionality of these concepts has been verified by two model systems consisting of three parts: (i) fluorescent aminoBODIPY for real-time detection of conjugate cleavage, (ii) a c(RGDfK) peptide specific for αvβ3 integrin receptors targeting angiogenesis in most solid tumors or redBODIPY for conjugate cleavage monitoring via FRET, and (iii) pegylated-2-phenyl-3-hydroxy-4(1H)-quinolinone (3HQ) as a model drug. The model drug release is based on a self-immolative disulfide linker sensitive to environments containing thiols, especially glutathione, which is overexpressed in cancer cells. The results show effective thiol-mediated cleavage of the fluorescent reporter and the subsequent liberation of the drug in a tube. The conjugate with c(RGDfK) was confirmed to penetrate the cells via interaction with integrin receptors. Drug release from this conjugate is possible to monitor inside the cells. Further, the synthetic approach to the conjugates and the method of fluorescence monitoring of the drug release have also been described.
- 650 _2
- $a sloučeniny boru $x chemie $7 D001896
- 650 _2
- $a nosiče léků $x chemie $x farmakologie $7 D004337
- 650 _2
- $a uvolňování léčiv $7 D065546
- 650 _2
- $a fluorescence $7 D005453
- 650 _2
- $a fluorescenční barviva $x chemie $7 D005456
- 650 _2
- $a glutathion $x metabolismus $7 D005978
- 650 _2
- $a HeLa buňky $7 D006367
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hydroxychinoliny $x aplikace a dávkování $x farmakokinetika $7 D006912
- 650 _2
- $a integrin alfaVbeta3 $x metabolismus $7 D039302
- 650 _2
- $a oligopeptidy $x chemie $x farmakologie $7 D009842
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Gurská, Soňa $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, Hněvotínská 5, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Stanková, Jarmila $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, Hněvotínská 5, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Hajdúch, Marián $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, Hněvotínská 5, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Džubák, Petr $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, Hněvotínská 5, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Hlaváč, Jan $u Department of Organic Chemistry, Faculty of Science, Palacký University, Tr. 17. Listopadu 12, 771 46 Olomouc, Czech Republic
- 773 0_
- $w MED00008279 $t Molecular pharmaceutics $x 1543-8392 $g Roč. 18, č. 6 (2021), s. 2385-2396
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33961440 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220113 $b ABA008
- 991 __
- $a 20220127145421 $b ABA008
- 999 __
- $a ok $b bmc $g 1751628 $s 1155376
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 18 $c 6 $d 2385-2396 $e 20210507 $i 1543-8392 $m Molecular pharmaceutics $n Mol Pharm $x MED00008279
- LZP __
- $a Pubmed-20220113